兴齐眼药：盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组

Core Viewpoint - The company has initiated the Phase III clinical trial for its lidocaine hydrochloride eye gel, which is intended for surface anesthesia in ophthalmic procedures, following the successful enrollment of the first subject in a randomized, double-blind, positive drug parallel control, and placebo parallel control multi-center clinical trial [1] Summary by Relevant Sections - Product Development - The lidocaine hydrochloride eye gel is designed to enhance the effectiveness of anesthesia by prolonging the contact time with the eye surface [1] - This product is currently the only one approved for market by Sichuan Heyi Pharmaceutical Co., Ltd. [1] - Clinical Trial Progress - The company has completed the enrollment of the first subject in the Phase III clinical trial, marking a significant milestone in the product's development [1] - The trial aims to evaluate the efficacy and safety of the eye gel for surface anesthesia [1] - Financial Impact - The initiation of the Phase III clinical trial is not expected to have a significant impact on the company's recent financial performance [1]